Selective toxicity of rifamycin derivatives for leukaemic human leucocytes.
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D002247:Carbon Isotopes; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D004254:DNA Nucleotidyltransferases / Q000037:antagonists & inhibitors; D004273:DNA, Neoplasm / Q000096:biosynthesis; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology; D007700:Kinetics; D007938:Leukemia / Q000097:blood* / Q000201:enzymology / Q000378:metabolism; D007962:Leukocytes / Q000187:drug effects* / Q000378:metabolism; D008214:Lymphocytes / Q000187:drug effects; D015122:Mercaptopurine / Q000494:pharmacology; D008727:Methotrexate / Q000494:pharmacology; D012334:RNA, Neoplasm / Q000096:biosynthesis; D012293:Rifampin / Q000494:pharmacology*; D013936:Thymidine / Q000378:metabolism; D014316:Tritium; D014529:Uridine / Q000378:metabolism
D000903:Antibiotics, Antineoplastic; D002247:Carbon Isotopes; D004273:DNA, Neoplasm; D012334:RNA, Neoplasm; D014316:Tritium; D015122:Mercaptopurine; D004254:DNA Nucleotidyltransferases; D013936:Thymidine; D012293:Rifampin; D014529:Uridine; D006918:Hydroxyurea; D008727:Methotrexate